A detailed history of Jpmorgan Chase & CO transactions in Abb Vie Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 51,258,003 shares of ABBV stock, worth $8.53 Billion. This represents 0.85% of its overall portfolio holdings.

Number of Shares
51,258,003
Previous 51,818,311 1.08%
Holding current value
$8.53 Billion
Previous $8.03 Billion 16.24%
% of portfolio
0.85%
Previous 0.84%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$159.82 - $182.1 $89.5 Million - $102 Million
-560,308 Reduced 1.08%
51,258,003 $9.33 Billion
Q4 2023

Feb 12, 2024

SELL
$137.6 - $154.97 $470 Million - $529 Million
-3,412,497 Reduced 6.18%
51,818,311 $8.03 Billion
Q3 2023

Nov 14, 2023

SELL
$133.59 - $154.65 $206 Million - $238 Million
-1,541,772 Reduced 2.72%
55,230,808 $8.23 Billion
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $149 Million - $186 Million
-1,125,984 Reduced 1.94%
56,772,580 $7.65 Billion
Q1 2023

May 18, 2023

BUY
$144.61 - $166.54 $120 Million - $139 Million
832,342 Added 1.46%
57,898,564 $9.23 Billion
Q1 2023

May 11, 2023

SELL
$144.61 - $166.54 $556 Million - $640 Million
-3,843,992 Reduced 6.31%
57,066,222 $9.09 Billion
Q4 2022

Feb 13, 2023

BUY
$138.31 - $165.87 $336 Million - $403 Million
2,431,205 Added 4.16%
60,910,214 $9.84 Billion
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $318 Million - $365 Million
2,368,374 Added 4.22%
58,479,009 $7.85 Billion
Q2 2022

Aug 11, 2022

BUY
$137.62 - $174.96 $278 Million - $353 Million
2,016,437 Added 3.73%
56,110,635 $8.59 Billion
Q1 2022

May 11, 2022

BUY
$131.98 - $163.75 $1.45 Billion - $1.8 Billion
10,989,210 Added 25.49%
54,094,198 $8.77 Billion
Q4 2021

Feb 10, 2022

SELL
$107.43 - $135.93 $84.7 Million - $107 Million
-788,370 Reduced 1.8%
43,104,988 $5.84 Billion
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $4.67 Billion - $5.3 Billion
43,893,358 New
43,893,358 $4.73 Billion

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $294B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.